Lipocalin-2 expressed in innate immune cells is an endogenous inhibitor of inflammation in murine nephrotoxic serum nephritis

PLoS One. 2013 Jul 4;8(7):e67693. doi: 10.1371/journal.pone.0067693. Print 2013.

Abstract

Lipocalin-2 (Lcn-2) is involved in divergent processes such as acute kidney injury or bacterial host defence. Our study was designed to evaluate the functional role of Lcn-2 in nephrotoxic serum nephritis (NTS). Since Lcn-2 is expressed in tubular epithelial cells as well as in cells of innate immunity such as macrophages and polymorphonuclear neutrophils (PMN), we induced NTS in wild-type (WT), Lcn-2 knock-out (KO) mice and WT/Lcn-2 KO chimeras. Mice lacking Lcn-2 exhibited more glomerular damage with increased proteinuria and interstitial leukocyte accumulation compared to WT mice. Chimeras able to express Lcn-2 in macrophages and PMN but not in epithelial cells were found to develop NTS comparable to wild-type controls. In contrast, chimeras expressing Lcn-2 in tubular epithelial cells with no expression in innate immune cells developed increased NTS due to decreased concerted apoptosis but increased necrosis and formation of damage-associated molecular patterns (DAMPs) such as high-mobility group box 1 (HMGB-1) in the kidney. In vivo blockade of HMGB-1, a toll-like receptor (TLR)-2 agonist, significantly reduced inflammation and NTS in Lcn-2 knock-out mice. In parallel, TLR-2 signalling was found to drive Lcn-2 transcription in vitro. Taken together, Lcn-2 expressed in innate immune cells is protective in NTS by inducing concerted apoptosis and inhibiting the formation of HMGB-1 thereby limiting cytokine production via TLR-2 signalling. In parallel, TLR-2 dependent transcription of Lcn-2 is an endogenous inhibitor of inflammation in NTS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute-Phase Proteins / deficiency
  • Acute-Phase Proteins / genetics*
  • Acute-Phase Proteins / immunology
  • Animals
  • Apoptosis
  • Cytokines / biosynthesis
  • Cytokines / immunology
  • Female
  • Gene Expression Regulation
  • HMGB1 Protein / genetics
  • HMGB1 Protein / immunology
  • Immunity, Innate
  • Inflammation
  • Kidney Glomerulus / immunology
  • Kidney Glomerulus / metabolism*
  • Kidney Glomerulus / pathology
  • Lipocalin-2
  • Lipocalins / genetics*
  • Lipocalins / immunology
  • Macrophages / immunology
  • Macrophages / metabolism*
  • Macrophages / pathology
  • Mice
  • Mice, Knockout
  • Nephritis / genetics*
  • Nephritis / immunology
  • Nephritis / metabolism
  • Nephritis / pathology
  • Neutrophils / immunology
  • Neutrophils / metabolism*
  • Neutrophils / pathology
  • Oncogene Proteins / deficiency
  • Oncogene Proteins / genetics*
  • Oncogene Proteins / immunology
  • Proteinuria / genetics*
  • Proteinuria / immunology
  • Proteinuria / metabolism
  • Proteinuria / pathology
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / immunology
  • Signal Transduction
  • Toll-Like Receptor 2 / antagonists & inhibitors
  • Toll-Like Receptor 2 / genetics
  • Toll-Like Receptor 2 / immunology

Substances

  • Acute-Phase Proteins
  • Cytokines
  • HMGB1 Protein
  • HMGB1 protein, mouse
  • Lipocalin-2
  • Lipocalins
  • Oncogene Proteins
  • RNA, Small Interfering
  • Tlr2 protein, mouse
  • Toll-Like Receptor 2
  • Lcn2 protein, mouse

Grants and funding

The work was supported by the “Tiroler Wissenschaftsfonds” (to KE), by the Austrian Research Funds (to ARR, P-21402; to GW, P-19664), by the Austrian National Bank Funds (to IT; Project 14182) and the PhD-program of the Medical University of Graz. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.